drugset / Trial / NCT03605927
CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease
Phase 1
Completed
45 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb · collab
NaSingle-groupOpen-labelPrevention
Summary
The purpose of this study is to examine the safety and efficacy of the addition of BMS-986004 to standard of care Sirolimus (SIR)-based immune suppression.
Timeline
- Start
- 2019-02-15
- Primary completion
- 2023-07-25
- Completion
- 2023-07-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LETOLIZUMAB | Monoclonal antibody | 225 mg | Intravenous |
| Subject | LETOLIZUMAB | Monoclonal antibody | 675 mg | Intravenous |
| Subject | LETOLIZUMAB | Monoclonal antibody | 1500 mg | Intravenous |
| Background | Sirolimus | Small molecule | — | Oral |
| Background | Tacrolimus | Small molecule | — | Intravenous |